- Home
- ANIP
as 11-15-2024 4:00pm EST
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid dose products. Its areas of product development include narcotics, oncolytic, hormones and steroids, and complex formulations involving extended release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | BAUDETTE |
| Market Cap: | 1.3B | IPO Year: | N/A |
| Target Price: | $76.80 | AVG Volume (30 days): | 278.1K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $48.20 - $70.81 | Next Earning Date: | 11-08-2024 |
| Revenue: | $555,456,000 | Revenue Growth: | 23.60% |
| Revenue Growth (this year): | 23.69% | Revenue Growth (next year): | 18.95% |
Stock Insider Trading Activity of ANI Pharmaceuticals Inc. (ANIP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Oct 14 '24 | Sell | $57.19 | 250 | $14,297.50 | 56,488 | |
| Cook Meredith | ANIP | SR. VP, GENERAL COUNSEL & SEC. | Sep 13 '24 | Sell | $56.82 | 250 | $14,205.00 | 56,488 |
Latest ANI Pharmaceuticals Inc. News
ANIP Breaking Stock News: Dive into ANIP Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
Are Investors Undervaluing ANI Pharmaceuticals (ANIP) Right Now?
Argus Research
5 days ago
ANIP: Raising target price to $64.00
Simply Wall St.
7 days ago
ANI Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GuruFocus.com
8 days ago
ANI Pharmaceuticals Inc (ANIP) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Zacks
9 days ago
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
Zacks
9 days ago
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
MT Newswires
9 days ago
ANI Pharmaceuticals' Q3 Adjusted Earnings, Net Revenue Rise; Fiscal 2024 Outlook Lifted
Associated Press Finance
9 days ago
ANI: Q3 Earnings Snapshot
Compare ANIP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANIP ANI Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.